Sudden onset agranulocytosis and hepatotoxicity after taking methimazole

Internal Medicine

Volumn 51, Issue 16, 2012, Pages 2189-2192

  Yang, Jing ^a   Zhong, Jing ^a   Zhou, Ling Zhi ^a   Hong, Tao ^a   Xiao, Xin Hua ^a   Wen, Ge Bo ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Agranulocytosis; Hepatotoxicity; Hyperthyroidism; Methimazole

Indexed keywords

BILIRUBIN GLUCURONIDE; GLUTATHIONE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IODINE 131; PIPERACILLIN; PROPRANOLOL; TAZOBACTAM; THIAMAZOLE;

ADULT; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE MARROW BIOPSY; CASE REPORT; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ECHOGRAPHY; ELECTROCARDIOGRAPHY; EYE DISEASE; FEMALE; FEVER; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GOITER; GRANULOCYTE PRECURSOR; GRAVES DISEASE; HAND TREMOR; HEART PALPITATION; HUMAN; HUMAN TISSUE; HYPERGAMMAGLOBULINEMIA; HYPERPLASIA; LIVER TOXICITY; LUNG INFECTION; MENSTRUAL IRREGULARITY; NEUTROPHIL COUNT; REVIEW; SINUS TACHYCARDIA; SWEATING; THORAX RADIOGRAPHY; THYROTROPIN BLOOD LEVEL; TONSILLITIS; WEIGHT REDUCTION;

ADULT; AGRANULOCYTOSIS; ANTITHYROID AGENTS; BONE MARROW; DRUG TOXICITY; FEMALE; GRAVES DISEASE; HUMANS; LIVER; METHIMAZOLE; TIME FACTORS;

EID: 84865147520     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7845     Document Type: Review

References (25)

1. He CT, Hsieh AT, Pei D, et al. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism. Clin Endocrinol (Oxf) 60: 676-681, 2004.
2. Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab 95: 2227-2233, 2010.
3. Cooper DS. Antithyroid drugs. N Engl J Med 352: 905-917, 2005.
4. Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid 14: 459-462, 2004.
5. Woeber KA. Methimazole-induced hepatotoxicity. Endocr Pract 8: 222-224, 2002.
6. Vilchez FJ, Torres I, Garcia-Valero A, Lopez-Tinoco C, de Los Santos A, Aguilar-Diosdado M. Concomitant agranulocytosis and hepatotoxicity after treatment with carbimazole. Ann Pharmacother 40: 2059-2063, 2006.
7. Jain K, Chakrapani M, Smitha K. Acute cholestatic hepatitis along with agranulocytosis: a rare side effect of carbimazole. Ann Afr Med 9: 102-104, 2010.
8. Takata K, Kubota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 19: 559-563, 2009.
9. Waldhauser L, Uetrecht J. Oxidation of propylthiouracil to reactive metabolites by activated neutrophils. Implications for agranulocytosis. Drug Metab Dispos 19: 354-359, 1991.
10. Pisciotta AV. Immune and toxic mechanisms in drug-induced agranulocytosis. Semin Hematol 10: 279-310, 1973.
11. Meyer-Gessner M, Benker G, Lederbogen S, Olbricht T, Reinwein D. Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature. J Endocrinol Invest 17: 29-36, 1994.
12. Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 98: 26-29, 1983.
13. Tsuboi K, Ueshiba H, Shimojo M, et al. The relation of initial methimazole dose to the incidence of methimazole-induced agranulocytosis in patients with Graves' disease. Endocr J 54: 39-43, 2007.
14. Sun MT, Tsai CH, Shih KC. Antithyroid drug-induced agranulocytosis. J Chin Med Assoc 72: 438-441, 2009.
15. Andres E, Zimmer J, Mecili M, Weitten T, Alt M, Maloisel F. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol 4: 143-151, 2011.
16. Apinantriyo B, Lekhakula A, Rujirojindakul P. Incidence, etiology and bone marrow characteristics of non-chemotherapy-induced agranulocytosis. Hematology 16: 50-53, 2011.
17. Douer D, Eisenstein Z. Methimazole-induced agranulocytosis: growth inhibition of myeloid progenitor cells by the patient's serum. Eur J Haematol 40: 91-94, 1988.
18. Akamizu T, Ozaki S, Hiratani H, et al. Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity. Clin Exp Immunol 127: 92-98, 2002.
19. Sera N, Ashizawa K, Ando T, et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid 10: 595-599, 2000.
20. Wall JR, Fang SL, Kuroki T, Ingbar SH, Braverman LE. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis. J Clin Endocrinol Metab 58: 868-872, 1984.
21. Ruiz JK, Rossi GV, Vallejos HA, Brenet RW, Lopez IB, Escribano AA. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother 37: 224-228, 2003.
22. Livadas S, Xyrafis X, Economou F, et al. Liver failure due to antithyroid drugs: report of a case and literature review. Endocrine 38: 24-28, 2010.
23. Arab DM, Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 80: 1083-1085, 1995.
24. Hanson JS. Propylthiouracil and hepatitis. Two cases and a review of the literature. Arch Intern Med 144: 994-996, 1984.
25. Gallelli L, Staltari O, Palleria C, De Sarro G, Ferraro M. Hepatotoxicity induced by methimazole in a previously healthy patient. Curr Drug Saf 4: 204-206, 2009.